Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-APT 1: Upamostat for early outpatient COVID-19
PACTR202410841571933Phase 2Recruiting
- Sponsor
- FHI Clinical
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Upamostat with Upamostat placebo (2 arms). Started Jan 2024; status: recruiting.
02
Drugs
upamostat
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202410841571933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202410841571933.